Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I
Srđan Verstovšek(Unknown), H. Kantarjian(The University of Texas MD Anderson Cancer Center), Murat O. Arcasoy(Duke University), Roger M. Lyons(Hematology Oncology Associates), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Richard T. Silver(Cornell University), Kris Vaddi(Wilmington University), John F. DiPersio(Washington University in St. Louis), Jason Gotlib(Stanford University), Vikas Gupta(Indian Institute of Technology Kanpur), Azra Raza(University of Illinois Chicago), William Sun(Incyte (United States)), Elizabeth O. Hexner(University of Pennsylvania), Richard S. Levy(Incyte (United States)), Carole B. Miller(Saint Agnes Hospital), Jimmie H. Harvey, Ronald Paquette, E. Winton(Emory University), Susan Erickson‐Viitanen(Incyte (United States)), V. Sandor(Incyte (United States)), Michael W. Deininger(Versiti Blood Center of Wisconsin), John Catalano(Frankston Hospital), Moshe Talpaz(University of Michigan)
Cited by 162
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
|Cancer Cell|2002|1.6k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k